全文获取类型
收费全文 | 2924篇 |
免费 | 209篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 157篇 |
妇产科学 | 46篇 |
基础医学 | 352篇 |
口腔科学 | 56篇 |
临床医学 | 265篇 |
内科学 | 759篇 |
皮肤病学 | 57篇 |
神经病学 | 183篇 |
特种医学 | 343篇 |
外科学 | 377篇 |
综合类 | 19篇 |
预防医学 | 198篇 |
眼科学 | 19篇 |
药学 | 123篇 |
中国医学 | 6篇 |
肿瘤学 | 179篇 |
出版年
2023年 | 13篇 |
2022年 | 25篇 |
2021年 | 56篇 |
2020年 | 43篇 |
2019年 | 55篇 |
2018年 | 66篇 |
2017年 | 57篇 |
2016年 | 43篇 |
2015年 | 61篇 |
2014年 | 67篇 |
2013年 | 96篇 |
2012年 | 110篇 |
2011年 | 122篇 |
2010年 | 89篇 |
2009年 | 80篇 |
2008年 | 109篇 |
2007年 | 131篇 |
2006年 | 145篇 |
2005年 | 128篇 |
2004年 | 116篇 |
2003年 | 105篇 |
2002年 | 105篇 |
2001年 | 95篇 |
2000年 | 88篇 |
1999年 | 87篇 |
1998年 | 108篇 |
1997年 | 84篇 |
1996年 | 89篇 |
1995年 | 58篇 |
1994年 | 59篇 |
1993年 | 71篇 |
1992年 | 48篇 |
1991年 | 42篇 |
1990年 | 25篇 |
1989年 | 58篇 |
1988年 | 32篇 |
1987年 | 49篇 |
1986年 | 37篇 |
1985年 | 37篇 |
1984年 | 26篇 |
1983年 | 18篇 |
1982年 | 29篇 |
1981年 | 32篇 |
1980年 | 31篇 |
1979年 | 10篇 |
1978年 | 16篇 |
1977年 | 23篇 |
1976年 | 24篇 |
1975年 | 19篇 |
1974年 | 6篇 |
排序方式: 共有3152条查询结果,搜索用时 20 毫秒
101.
Valcárcel D Martino R Sureda A Canals C Altés A Briones J Sanz MA Parody R Constans M Villela SL Brunet S Sierra J 《European journal of haematology》2005,74(2):144-151
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)-compatible sibling donors is a potential curative treatment for hematological and non-hematological malignancies. Nevertheless, high mortality rates may be associated with this therapy, especially in older patients, those with other comorbidities or who receive a second HSCT. PATIENTS AND METHODS: We analyzed the factors associated with transplant-related mortality (TRM) and overall survival in 157 consecutive adult patients (104 males and 53 females) who received a HSCT [29 bone marrow (BM) transplantation and 128 peripheral blood (PB) transplantation] from a HLA-identical sibling between January 1995 and March 2002 in our institution. One hundred patients received a standard conditioning prior to HSCT (STAND) and 57 patients received a reduced-intensity conditioning (RIC) HSCT. Fifty-eight patients were in an early phase at transplant and 99 in a non-early phase. Median age was 46 yr (16-66), and 90 patients (57%) were >45 yr of age. RESULTS: Patients in the RIC group were older than those in the STAND group, and had a higher proportion of non-early disease phases including a prior autologous HSCT in 39%. Median follow-up for survivors was 28 and 15 months in the STAND and RIC groups (P < 0,001), respectively. Cumulative incidence of TRM at 2 yr was 30% [95% confidence interval (CI) 22-41%] for the STAND group and 22% (95% CI 13-37%) for the RIC group [non-significant (NS)]. Factors associated with a higher TRM in multivariate analysis were: STAND vs. RIC conditioning regimen [relative risk (RR) 5.4; 95% CI 2.3-12.8; P < 0.001]; age > or =45 yr vs. <45 yr (RR 5; 95% CI 2.4-10.8, P < 0.001); second vs. first HSCT (RR 2.8, 95% CI 1.3-6.3, P = 0.01) and non-T-cell-depleted vs. T-cell-depleted graft (RR 2.7, 95% CI 1.3-5.8, P = 0.009). Overall survival (OS) at 2 yr was 52.5 +/- 10.4% for STAND group and 59 +/- 16.8% in RIC group. Factors associated with poorer OS in multivariate analysis were: STAND vs. RIC conditioning regimen (RR 3.4, 95% CI 1.7-6.9, P = 0.001); age > or =45 vs <45 yr (RR 2.5, 95% CI 1.4-4.5, P = 0.002) and diagnosis [other than chronic myeloid leukemia (CML) vs. CML] (RR 2.6, 95% CI 1.2-5.7 P = 0.02). CONCLUSIONS: Our results indicate that the introduction of RIC allogeneic HSCT for patients at high risk for TRM (advanced age, prior HSCT and non-T-cell depletion) leads to a reduction in the TRM and improvement in the OS. 相似文献
102.
103.
Burri H Vuille C Sierra J Didier D Lerch R Kalangos A 《Echocardiography (Mount Kisco, N.Y.)》2003,20(2):185-189
Drainage of the inferior vena cava to the left atrium is an extremely unusual congenital heart disease. We describe a 54-year-old woman, in whom the diagnosis was suggested by transthoracic echocardiography, and then confirmed by a transesophageal exam and magnetic resonance imaging, which also revealed an associated secundum atrial septal defect. Surgical management involved reconstruction of the interatrial septum to include the inferior vena cava in the right atrium. The few previously reported cases in the literature are reviewed. 相似文献
104.
Sanz-Ortega J Hernández S Saez MC Sierra E Sanz-Ortega G Torres A Balibrea JL Sanz-Esponera J Merino MJ 《Hepato-gastroenterology》2003,50(50):404-407
BACKGROUND/AIMS: A common genetic abnormality detected in Barrett's adenocarcinoma is LOH (loss of heterozygosity) at the sites of known or putative tumor suppressor genes. Thus, some deletions have also been determined in peritumoral Barrett's epithelium. These findings suggest that a tissue field of somatic genetic alterations precede the histopathological phenotypic changes of carcinoma. We investigated 32 cases of Barrett's esophagus with no evidence of dysplasia for LOH at 5q21 (APC), 3p21, 9p21 (p16) and 17p13.1 (p53) chromosomal regions. METHODOLOGY: Two groups were randomly selected and compared: 16 cases of Barrett's epithelium adjacent to adenocarcinoma and 16 cases of Barrett's epithelium with no evidence of malignant transformation in a 5-10 years follow-up period. In three adenocarcinomas cases several previous endoscopic biopsies of Barrett's esophagus were available. RESULTS: We determined frequent allelic losses in adenocarcinomas at p53 (54%), p16 (50%), 3p21 (40%) and 5q21 (33%). Identical LOH was present in most cases in the Barrett's epithelium adjacent to adenocarcinoma. LOH at these loci was unusual in Barrett's epithelium with no evidence of malignant transformation. However, in cases where sequential endoscopic biopsies were performed in advance to the adenocarcinoma diagnosis LOH was already present in the Barrett's epithelium. CONCLUSIONS: We suggest that LOH at these loci may be present before the onset of the malignant growth and LOH studies may supplement the histopathological evaluation of Barrett's epithelium. LOH at 3p21, 5q21, 9p21 and 17p13 chromosomal regions in cells of Barrett's epithelium without dysplasia may have a role as a potential marker for individuals with a high risk of developing adenocarcinoma. 相似文献
105.
106.
Gómez-Núñez M Martino R Caballero MD Pérez-Simón JA Canals C Mateos MV Sarrá J León A Solano C Moraleda JM Urbano-Ispizua A Besalduch J Miguel JS Sierra J 《Bone marrow transplantation》2004,33(5):477-482
Over a 3-year period, 145 patients ineligible for myeloablative conditioning underwent reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (SCT) from an HLA-identical sibling in a prospective study. The median age was 54 years, 88 patients were male and 61 patients were beyond the early-intermediate phase of their disease. The 100-day probability of developing grade II-IV acute graft-versus-host disease (GVHD) was 34%, and the 1-year probability of developing chronic extensive GVHD was 41%. The 1-year probabilities of transplant-related mortality (TRM), overall (OS) and progression-free survival were 20, 60 and 52%, respectively. Multivariate analyses found a better OS in: (i) patients <60 years; and (ii) recipients of a first SCT; and a higher TRM in: (i) age >60 years, (ii) recipients of a prior autologous SCT, and (iii) an ECOG performance status >1. The 1-year TRM in patients with 0 or 1 and >2 of the above-mentioned adverse prognostic factors were 17 vs 53%, respectively (P<0.001). In summary, our study shows that elderly patients have a higher TRM following an RIC protocol. However, age by itself should not preclude these RIC transplants, since TRM appears to be unacceptably high only in the presence of additional adverse factors. 相似文献
107.
Alain P. Gobert Olivier Boutaud Mohammad Asim Irene A. Zagol-Ikapitte Alberto G. Delgado Yvonne L. Latour Jordan L. Finley Kshipra Singh Thomas G. Verriere Margaret M. Allaman Daniel P. Barry Kara M. McNamara Johanna C. Sierra Venkataraman Amarnath Mohammed N. Tantawy Diane Bimczok M. Blanca Piazuelo M. Kay Washington Keith T. Wilson 《Gastroenterology》2021,160(4):1256-1268.e9
- Download : Download high-res image (348KB)
- Download : Download full-size image
108.
Carrasco M Muñoz L Bellido M Bernat S Rubiol E Ubeda J Sierra J Nomdedéu JF 《Annals of hematology》2000,79(6):299-303
Antibodies against CD66 identify antigens from the carcinoembryonic antigen (CEA) family of proteins, which belong to the
immunoglobulin gene superfamily. Despite being usually restricted to cells of myeloid or monocytic origin, CD66 expression
has also been reported in blasts from children with B-cell lineage acute lymphocytic leukaemia (ALL). An analysis of the CD66
expression was undertaken in a series of acute leukaemia patients. Antigenic expression was analysed using triple combinations
of monoclonal antibodies (mAbs) in forty-five patients. The CD66 Kat4 fluorescein isothiocyanate clone was purchased from
Dako (Glostrup, Denmark). CD66 was expressed in 2 of 29 patients with AML (acute myeloblastic leukemia) (6.8%) and in 8 of
12 patients with B-cell lineage ALL (66.7%; P <0.001); in blast crisis (BC) of chronic myelocytic leukaemia (CML), CD66 was expressed in two patients with lymphoid BC
but not in the two with myeloid BC. The co-expression of CD66 with other myeloid antigens was observed in all CD66+ ALL/Ly-BC
cases tested: CD 13 in six patients, CD33 in seven and CD117 in two patients. The CD66 expression is more frequent in ALL
than in AML. Furthermore, we analysed minimal residual disease (MRD) in eight patients in complete remission. CD66 expression
was associated with an abnormal B-cell differentiation pattern and with increases in CD34/CD19+ cells in all but one case.
These findings suggest that an aberrant expression of CD66 could be used to investigate MRD in ALL. The association between
CD66 reactivity and bcr-abl in adult ALL remains to be investigated.
Received: 31 May 1999 / Accepted: 10 November 1999 相似文献
109.
Subirà M Sureda A Ancín I Martino R Altés A Brunet S Sierra J 《Bone marrow transplantation》2003,32(9):869-872
Allogeneic stem cell transplantation (allo-SCT) after a reduced-intensity conditioning (RIC) protocol is associated with decreased short-term toxicity. This suggests that the procedure could be performed on an outpatient basis. We analysed the incidence and risk factors of grade >or=2 conditioning-related toxicities (CRTs) as a hallmark for hospital admission, in 41 consecutive patients allografted from an HLA identical sibling after RIC. The RIC regimen consisted of fludarabine plus melphalan for lymphoid malignancies, and fludarabine plus busulphan for myeloid malignancies. In all, 11 patients (27%) did not experience any toxicity. The more frequent CRTs observed were neutropenic fever and gastrointestinal toxicity. The median duration of hospitalisation was 27 (range, 17-50) days. If allo-SCT had been planned as an outpatient procedure and admission indicated only in the case of >or=2 CRTs, the inpatient period would have decreased to 9 (range, 0-33) days (P<0.001). No risk factors for CRTs were identified. Allo-SCT after an RIC regimen is a well-tolerated procedure. Our results warrant a prospective pilot trial of nonmyeloablative allo-SCT performed in the outpatient setting. 相似文献
110.
P Martínez‐Montero M Muoz‐Calero E Vallespín J Campistol L Martorell MJ Ruiz‐Falc A Santana R Pons A Dinopoulos C Sierra J Nevado J Molano 《Clinical genetics》2013,84(6):566-571
Pelizaeus–Merzbacher disease (PMD) is caused in most cases by either duplications or point mutations in the PLP1 gene. This disease, a dysmyelinating disorder affecting mainly the central nervous system, has a wide clinical spectrum and its causing mutations act through different molecular mechanisms. Eighty‐eight male patients with leukodystrophy were studied. PLP1 gene analysis was performed by the Multiplex Ligation‐dependent Probe Amplification technique and DNA sequencing, and, in duplicated cases of PLP1, gene dosage was completed by using array‐CGH. We have identified 21 patients with mutations in the PLP1 gene, including duplications, short and large deletions and several point mutations in our cohort. A customized array‐CGH at the Xq22.2 area identified several complex rearrangements within the PLP1 gene region. Mutations found in the PLP1 gene are the cause of PMD in around 20% of the patients in this series. 相似文献